White cell disease Flashcards
Myeloperoxidase (MPO) is a marker of…
AML
PML-RARA
APL
t(15;17)
APL (PML-RARA)
Which FAB classification does APL belong to?
AML-M3
Pathogenesis and management of APL differentiation syndrome
Pathogenesis: release of inflammatory cytokines from malignant promyelocytes after ATRA –> capillary leak
Management: Dexamethasone, restart ATRA after resolution
Myeloblast vs Lymphoblast (5)
relatively low N:C ratio; very high
fine granules; agranular
fine chromatin; clumped
prominent nucleoli; indistinct
Auer rods
Cytogenetic studies for prognosis of ALL (3)
t(9;22) (poor)
t(12;21) (good)
hyperdiploidy (good)
Diagnostic criteria for Polycythaemia vera
Major:
- erythrocytosis
1. Hb > 18.5 / 16
2. Hct >49%
3. ↑ red cell mass
- BM briopsy: hyperceullar with trilineage growth
- JAK2
Minor:
- subnormal EPO
all majors, or major 1+2 + minor
Diagnostic criteria for essential thrombocytopenia
- Plt >450
- BM biopsy: megakaryocytic proliferation
- JAK2 / CALR / MPL
- ⨉ other MPN
Diagnostic criteria for PMF
Major:
- BM biopsy: reticulin +/- collagen fibrosis
- BM biopsy: megakaryocytic proliferation & atypia
- JAK2 / CALR / MPL
- ⨉ other MPN
Minor:
- leucoerythroblastosis
- ↑ serum LDH
- anaemia
- splenomegaly
all majors + 1 minor
Which MPN can directly transform into AML? (3)
CML, PV, PMF
t(9;22)
Philadelphia (Ph) chromosome / BCR-ABL1
CML
3 phases of CML (blast %)
- Chronic phase (blast <10%)
- Accelerated phase (blast 10~19%)
- Blast crisis (blast >=20%)
TKI for CML (1+3+1)
1st generation: Imatinib
2nd generation: Nilotinib 尼洛, Dasatinib 達沙, Bosutinib 博舒
3rd generation: Ponatinib 普納
Role of treatment of Ponatinib in CML
for T315I mutation
Role of treatment of hydroxyurea in CML
cytoreduction while awaiting confirmation of diagnosis
3 types of responses in treatment of CML
- Complete haematological response
- Complete cytogenetic response
- Molecular response
Major molecular response definition
3 log reduction (of BCR-ABL1 transcript) compared to international scale
Management for PV (4)
aspirin, venesection
[high risk] hydroxyurea, ruxolitinib
Management for ET (2)
aspirin, anagrelide
Assessment for PMF
DIPSS Plus scoring
Cytogenetics studies for prognosis of MDS
del 5q (good)
Risk stratification of MDS (4 parameters)
IPSS
1. dysplasia (single / multiple lineage)
2. % of blasts
3. del 5q
4. % of sideroblasts
PIG-A mutation
Paroxysmal nocturnal haemoglobinuria
BRAF V600E
Hairy cell leukaemia
Which haematological malignancy is associated with HTLV-1?
Adult T-cell leukaemia / lymphoma (ATLL)
Which haematological malignancy is associated with TCR rearrangement?
Adult T-cell leukaemia / lymphoma (ATLL)
Classification of Hodgkin lymphoma (4+1)
- Classical (CD30+)
a. Nodular sclerosing
b. Mixed cellularity
c. Lymphocyte rich
d. Lymphocyte depleted - Nodular lymphocyte predominant HL
Staging for Hodgkin lymphoma
Ann Arbor staging
t(14;18) (associated protein)
Follicular lymphoma
↑ Bcl-2
t(11;14) (associated protein)
Mantle cell lymphoma
↑ cyclin D1
MYD88
Lymphoplasmacytic lymphoma
t(8;14) / IGH-MYC fusion
Burkitt lymphoma
t(2;5) / NPM1-ALK fusion
Anaplastic T-cell lymphoma
Which blood cancer comes with DIC?
APL
Which blood cancer often comes with monocytopenia?
Hairy cell leukaemia
Which blood cancer often comes with gum hypertrophy?
AML-M5 / AMoL
Which blood cancer comes often with CNS involvement?
ALL